Roche and BioMed X collaborate to develop nanomaterial-based biosensors for near-patient testing

Heidelberg (ots) - Heidelberg (ots) - Roche and BioMed X announced
today that they have entered into a collaboration agreement to
establish a research group focusing on the development of a novel
sensor technology platform based on new nanomaterials such as
graphene.

Outstanding early career scientists from leading academic
institutions world-wide are invited to submit original project
proposals in the fields of biotechnology, nanotechnology and
engineering. Roche and BioMed X will jointly select the best ideas
and research talents to form a new research group within BioMed X's
open innovation lab in Heidelberg. BioMed X has developed a unique
innovation model offering a project plan competition, an attractive
funding package, entrepreneurial education and guidance by
experienced mentors from academia and industry. BioMed X's open
innovation lab is part of the multi-disciplinary life science campus
of the University of Heidelberg which provides an inspiring,
interdisciplinary environment for project teams. The unique
supportive setting of BioMed X provides an exciting opportunity for
the winners of the project plan competition to combine
state-of-the-art nanomaterials research with biomedical know-how in
order to develop a new sensor technology platform for near-patient
testing.

BioMed X will be responsible for the operation of the innovation
center facility, providing entrepreneurial education and enabling
access to the Heidelberg scientific community and research
facilities.

"We have been looking into open innovation opportunities before and
are excited to work with BioMed X's novel and inspiring concept. What
we can do in this incubator complements our internal research
activities very well", said Matthias Essenpreis, Chief Technology
Officer of Roche Diagnostics. "We are particularly excited about our
collaboration with Roche since it extends our successful innovation
model into the new fields of diagnostics and nanotechnology", said
Christian Tidona, founder and Managing Director of BioMed X.

Further details of the agreement and financial terms are not
disclosed.

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | EUN

print